GT Biopharma price target lowered to $3 from $8 at Roth Capital

Roth Capital lowered the firm’s price target on GT Biopharma (GTBP) to $3 from $8 and keeps a Buy rating on the shares. As of January, GT Biopharma held pro forma cash of $9M, sufficient to fund operations through 2026, the analyst tells investors in a research note. The company is advancing its pipeline with a Phase 1 trial of second-generation TriKE GTB-3650 in relapsed/refractory CD33-positive hematologic malignancies, with initial data expected in 3Q26, and plans to start a Phase 1 basket trial of GTB-5550 in mid-2026 for B7-H3-expressing solid tumors, while financial models have been adjusted for increased dilution, the firm says.